Top Markets
#1 Velas Velas +367.73%
#2 Gravity Gravity +49.57%
#3 Galxe Galxe +41.03%
#4 Audiera Audiera +34.91%
#5 Infinity Ground Infinity Ground +30.81%
#6 Nosana Nosana +30.42%
#7 Aria.AI Aria.AI +21.94%
#8 Wiki Cat Wiki Cat +19.46%
#9 Derive Derive +18.93%
#10 Fetch.ai Fetch.ai +17.94%
Coin of the day
Velas Velas
Settings
Language
ENGLISH
Currency
USD
Theme
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NVO
Rank in Stocks #98
Novo Nordisk A/S, a healthcare company, engages in the research, development,... Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Share Price
$38.05
Market Cap
$169.07B
Change (1 day)
0.22%
Change (1 year)
-50.38%
Country
DK
Trade Novo Nordisk A/S (NVO)

Category

Healthcare
Market Capitalization
Revenue
more
Earnings
Price History
P/E Ratio
P/S Ratio
P/B Ratio
Operating Margin
EPS
Stock Splits
Dividends
Dividend Yield
Shares Outstanding
P/E ratio for Novo Nordisk A/S (NVO)
P/E ratio as of February 2026 TTM: 13.47
According to Novo Nordisk A/S latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 13.47. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Novo Nordisk A/S from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 123.72%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 26.43%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 125.91%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 145.46%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 38.30 184.27%
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.